Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3351-3358

  Meyer Gerspach, A C ^a   Steinert, R E ^a   Keller, S ^b   Malarski, A ^b   Schulte, F H ^a   Beglinger, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; C PEPTIDE; CHENODEOXYCHOLIC ACID; CHOLECYSTOKININ; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; OLEATE SODIUM; PEPTIDE YY; PLACEBO;

ARTICLE; BILE ACID BLOOD LEVEL; CHOLECYSTOKININ BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BILE ACIDS AND SALTS; C-PEPTIDE; CHENODEOXYCHOLIC ACID; CHOLECYSTOKININ; DIPEPTIDES; DOUBLE-BLIND METHOD; FIBROBLAST GROWTH FACTORS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; YOUNG ADULT;

EID: 84881538550     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4109     Document Type: Article

References (40)

1. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678-693.
2. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714-719.
3. Kawamata Y, Fujii R, Hosoya M, et al. A Gprotein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435-9440.
4. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362-1365.
5. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167-177.
6. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagonlike peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386-390.
7. Parker H, Wallis K, le Roux C, Wong K, Reimann F, Gribble F. Molecular mechanisms underlying bile acid-stimulated glucagonlike peptide-1 secretion. Br J Pharmacol. 2012;165(2):414-423.
8. Plaisancié P, Dumoulin V, Chayvialle JA, Cuber JC. Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol. 1995;145(3):521-526.
9. Armstrong DN, Krenz HK, Modlin IM, Ballantyne GH. Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum. Gut. 1993;34(4):483-488.
10. Ballantyne GH, Longo WE, Savoca PE, et al. Deoxycholate-stimulated release of peptide YY from the isolated perfused rabbit left colon. Am J Physiol. 1989;257(5 Pt 1):G715-G724.
11. Adrian TE, Ballantyne GH, Longo WE, et al. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut. 1993;34(9):1219-1224.
12. Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5): 474-477.
13. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012; 55(9):2343-2347.
14. Miyasaka K, Funakoshi A, Shikado F, Kitani K. Stimulatory and inhibitory effects of bile salts on rat pancreatic secretion. Gastroenterology. 1992;102(2):598-604.
15. Koop I, Dorn S, Koop H, et al. Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans. Dig Dis Sci. 1991;36(11):1625-1632.
16. van Ooteghem NA, Moschetta A, Rehfeld JF, Samsom M, van Erpecum KJ, van Berge-Henegouwen GP. Intraduodenal conjugated bile salts exert negative feedback control on gall bladder emptying in the fasting state without affecting cholecystokinin release or antroduodenal motility. Gut. 2002;50(5):669-674.
17. Portincasa P, Peeters TL, van Berge-Henegouwen GP, van Solinge WW, Palasciano G, van Erpecum KJ. Acute intraduodenal bile salt depletion leads to strong gallbladder contraction, altered antroduodenal motility and high plasma motilin levels in humans. Neurogastroenterol Motil. 2000;12(5):421-430.
18. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
19. Beglinger C, Degen L. Gastrointestinal satiety signals in humansphysiologic roles for GLP-1 and PYY? Physiol Behav. 2006;89(4): 460-464.
20. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man.AmJ Clin Nutr. 1981;34(2):154-160.
21. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 2007;117(1):13-23.
22. Schaap FG. Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2012;15(4): 386-391.
23. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006;260(6):530-536.
24. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621-1624.
25. Cyphert HA, Ge X, Kohan AB, Salati LM, Zhang Y, Hillgartner FB. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem. 2012; 287(30):25123-25138.
26. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635.
27. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPAR signaling. J Cell Physiol. 2007;210(1):1-6.
28. Penagini R, Misiewicz JJ, Frost PG. Effect of jejunal infusion of bile acids on small bowel transit and fasting jejunal motility in man. Gut. 1988;29(6):789-794.
29. Stengel A, Keire D, Goebel M, et al. The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides. Endocrinology. 2009; 150(11):5113-5118.
30. Gerspach AC, Steinert RE, Schonenberger L, Graber-Maier A, Beglinger C. The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. Am J Physiol Endocrinol Metab. 2011;301(2):E317-E325.
31. Keller S, Jahreis G. Determination of underivatised sterols and bile acid trimethyl silyl ether methyl esters by gas chromatography-mass spectrometry-single ion monitoring in faeces. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813(1-2):199-207.
32. Steinert RE, Meyer-Gerspach AC, Beglinger C. The role of the stomach in the control of appetite and the secretion of satiation peptides. Am J Physiol Endocrinol Metab. 2012;302(6):E666-E673.
33. Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery-a 1 year prospective randomized pilot trial. Obesity. doi:10.1002/oby.20522.
34. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613-3619.
35. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98(4):E708-E712.
36. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab. 2013;98(4):E718-E722.
37. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G419-G424.
38. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010;52(4):1455-1464.
39. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145(6):2594-2603.
40. Thimister PW, Hopman WP, Sloots CE, et al. Effect of bile salt binding or protease inactivation on plasma cholecystokinin and gallbladder responses to bombesin. Gastroenterology. 1994;107(6): 1627-1635.